View Older Stories View More Recent Stories

May 7, 2021 12:00AM China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
May 6, 2021 04:05PM BeiGene Reports First Quarter 2021 Financial Results
Apr 28, 2021 07:17AM BeiGene (BGNE) Announces BRUKINSA Demonstrates Superior OS Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutin
Apr 28, 2021 07:00AM BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against
Apr 12, 2021 01:33PM BeiGene (BGNE) Presents Interim Analysis of Phase 3 Trial of Tislelizumab in NSCLS at AACR
Apr 12, 2021 01:30PM BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
Apr 11, 2021 04:00PM BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
Apr 8, 2021 07:03AM BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints
Apr 8, 2021 07:00AM BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
Apr 8, 2021 07:00AM BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
Apr 7, 2021 07:00PM BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China
Mar 30, 2021 08:36AM BeiGene (BGNE) Names Julia Wang as New CFO
Mar 30, 2021 08:30AM BeiGene Announces New Chief Financial Officer, Julia Wang
Mar 17, 2021 06:50AM 111, Inc. Enters into First-Ever Strategic Partnership with BeiGene
Mar 10, 2021 04:30PM BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021
Mar 10, 2021 07:02AM BeiGene (BGNE) Doses First Patient in Phase 1 Trial of BGB-15025
Mar 10, 2021 07:00AM BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025
Mar 5, 2021 08:36AM BeiGene (BGNE) Announces Acceptance of sBLA in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer
Mar 5, 2021 08:30AM BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer
Mar 2, 2021 07:19AM BeiGene (BGNE) Announces Health Canada Approves BRUKINSA for Treatment of Waldenström’s Macroglobulinemia
Mar 2, 2021 07:00AM Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
Mar 2, 2021 07:00AM Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
Feb 26, 2021 07:00AM BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
Feb 25, 2021 04:05PM BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 17, 2021 05:00PM Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
Feb 17, 2021 07:05AM BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia
Feb 17, 2021 07:00AM BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia
Jan 27, 2021 05:46PM BeiGene (BGNE) Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
Jan 27, 2021 05:45PM BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
Jan 25, 2021 07:04AM EUSA Pharma and BeiGene (BGNE) Announce Acceptance of BLA for SYLVANT in China
Jan 25, 2021 07:00AM EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China
Jan 13, 2021 11:00PM China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer
Jan 11, 2021 04:31PM BeiGene (BGNE) Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
Jan 11, 2021 04:30PM BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
Jan 11, 2021 07:00AM Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology
Jan 7, 2021 07:00AM BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference
Dec 27, 2020 11:00PM BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)
Dec 7, 2020 07:00PM BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Dec 7, 2020 10:08AM BeiGene (BGNE) Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell Malignancies and Waldenström’s Macroglobulinemia at the 62nd ASH
Dec 7, 2020 10:00AM BeiGene Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell Malignancies and Waldenström’s Macroglobulinemia at the 62nd ASH Annual Meeting
Dec 6, 2020 12:30PM BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual
Nov 23, 2020 07:00AM BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 19, 2020 08:00PM BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma
Nov 17, 2020 07:04AM BeiGene (BGNE) Reports RATIONALE 303 Trial of Tislelizumab in NSCLC Met Primary Endpoint of OS at Interim Analysis
Nov 17, 2020 07:00AM BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis
Nov 9, 2020 07:25AM EUSA Pharma and BeiGene (BGNE) Announce Acceptance of Biologics License Application for QARZIBA in China
Nov 9, 2020 07:04AM EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China
Nov 5, 2020 04:05PM BeiGene Reports Third Quarter 2020 Financial Results
Nov 5, 2020 09:00AM BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting
Oct 6, 2020 07:07AM BioAtla and BeiGene (BGNE) Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071
View More Recent Stories View Older Stories